Onkure Therapeutics Inc
Officers & Directors
Nicholas A. Saccomano, Ph.D., age 67, serves as President, Chief Executive Officer, and Class I Director. He has over 30 years of experience in pharmaceutical and biotechnology research and development, having previously held positions as Chief Executive Officer and President of Legacy OnKure, Chief Science Officer at Pfizer Inc.'s Boulder facility, Chief Scientific Officer at Array BioPharma Inc., and Chief Technology Officer at SomaLogic. He holds a B.S. from the State University of New York at Buffalo and a Ph.D. in organic chemistry from Columbia University.
Jason Leverone, C.P.A., age 52, is Chief Financial Officer. He previously served as Chief Financial Officer at Legacy OnKure and has held CFO roles at Viridian Therapeutics and Replidyne, Inc. He is a Certified Public Accountant with a B.S. in business administration from Bryant University.
Samuel Agresta, M.D., age 53, is Chief Medical Officer. He formerly served as Chief Medical Officer at Legacy OnKure and held medical leadership positions at Foghorn Therapeutics Inc., Infinity Pharmaceuticals, Inc., Agios Pharmaceuticals Inc., Merrimack Pharmaceuticals, Inc., and Genentech, Inc. He holds a B.S. from Georgetown University, an M.P.H. and T.M. from Tulane School of Public Health and Tropical Medicine, an M.D. from Tulane University Medical School, and an M.S. in clinical investigation from the University of South Florida.
Dylan Hartley, Ph.D., age 57, is Chief Scientific Officer. He previously served as Chief Scientific Officer at Legacy OnKure and as Vice President, Head of Research at Pfizer Inc.'s Boulder facility (formerly Array BioPharma, Inc.). He has over 20 years of experience in drug research and development, with expertise in pharmacology, toxicology, drug metabolism, and pharmacokinetics.
Onkure Therapeutics Inc currently has 45 employees.
|
